SpyGlass Direct Visualization System Clinical Registry in China

Biliary Tract Diseases Clinical Trial

— SpyChina  

Official title:

Clinical Registry of Cholangioscopy Using the SpyGlass™ Direct Visualization System Throughout China

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02287194
• Other study ID #: E7101
• Status: Completed
• Start date: November 28, 2014
• Est. completion date: December 31, 2017

Study information

• Verified date: September 2017
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To document indications for cholangioscopy and clinical utility of the SpyGlass Direct Visualization System in China when used per standard of practice.

Prospective, Post market, Multi-center, Non-randomized Study

Description:

Patients who presenting with an indication for cholangioscopy or presenting with a possible indication for cholangioscopy to be determined during the ERCP procedure immediately preceding the SpyGlass procedure will join this study, totally 500 patients across 16 sites throughout China will participate in study. After SpyGlass operation, all patients will be followed for 72 hours to observe adverse events, and patients with indeterminate stricture or undefined filling defect indication with tissue sampling not yielding histopathology positive for malignancy and unresolved device and/or procedure related SAE at 72 Hours will continue to be followed up until 6 months. Finally, procedure success rate will be analyzed as primary endpoint, and SAEs and impact of patients management will be analyzed as secondary endpoint.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 197
• Est. completion date: December 31, 2017
• Est. primary completion date: April 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Age above 18 and not above 85.

2. Willing and able to provide written informed consent to participate in the study.

3. Willing and able to comply with the study procedures.

4. Indicated for ERCP and cholangioscopy or indicated for ERCP with suspected need for cholangioscopy.

Exclusion Criteria:

1. Endoscopic techniques are contraindicated.

2. ERCP is contraindicated

3. A medical condition that warrants the use of the device outside of the indication for use.

4. Requirement for anticoagulation that cannot be safely stopped at least 7 days prior to the procedure.

Related Conditions & MeSH terms

• Biliary Tract Diseases

Intervention

Device:
• SpyGlass
The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.

Locations

Country	Name	City	State
China	Shanghai Changhai Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Boston Scientific Corporation

Country where clinical trial is conducted

China, 

References & Publications (1)

Chen YK. Preclinical characterization of the Spyglass peroral cholangiopancreatoscopy system for direct access, visualization, and biopsy. Gastrointest Endosc. 2007 Feb;65(2):303-11. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Procedural success rate	For indeterminate strictures or undefined filling defects cases procedural success is defined as 1) ability to visualize stricture or defect, and 2) ability to provide visual impression of malignancy, and 3) when applicable, ability to obtain SpyBite biopsy adequate for histology; For biliary stone cases procedural success is defined as 1) ability to visualize the stone(s), and 2) ability to successfully initiate stone fragmentation, and 3) ability to achieve stone clearance in one or more SpyGlass procedures.; For other indications procedural success is defined as ability to establish diagnosis and /or complete therapy in the following categories: 1) pre-operative assessment of extent of peri-ampullary and biliary tumors, 2) selective guidewire placement, 3) assessment of unexplained hemobilia, 4) assessment of portal biliopathy, 5) assessment of intraductal biliary ablation therapy, 6) extraction of migrated stents, or 7) other.	72 hours
Secondary	Safety Endpoints	Evaluation of serious adverse events (SAEs) related to the SpyGlass devices and/or the SpyGlass procedure from enrollment through the 72 Hour Post Procedure Follow-up Visit.	Post Procedure